A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
Clinical trial NCT07259122 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07259122
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2028-06-30
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.